Diagnosis and Management of Pulmonary Hypertension
This book provides an overview of pulmonary hypertensive diseases, the current understanding of their pathobiology, and a contemporary approach to diagnosis and treatment. It discusses the definition and classification of these disorders and the epidemiol
- PDF / 10,116,894 Bytes
- 481 Pages / 439.43 x 683.15 pts Page_size
- 98 Downloads / 190 Views
James R. Klinger Robert P. Frantz Editors
Diagnosis and Management of Pulmonary Hypertension
Respiratory Medicine Series Editor: Sharon I.S. Rounds
More information about this series at http://www.springer.com/series/7665
James R. Klinger • Robert P. Frantz Editors
Diagnosis and Management of Pulmonary Hypertension
Editors James R. Klinger, MD Division of Pulmonary, Sleep and Critical Care Medicine Rhode Island Hospital Alpert Medical School of Brown University Providence, RI, USA
Robert P. Frantz, MD Department of Medicine Mayo Clinic College of Medicine Rochester, MN, USA
ISSN 2197-7372 ISSN 2197-7380 (electronic) Respiratory Medicine ISBN 978-1-4939-2635-0 ISBN 978-1-4939-2636-7 (eBook) DOI 10.1007/978-1-4939-2636-7 Library of Congress Control Number: 2015938155 Springer New York Heidelberg Dordrecht London © Springer Science+Business Media New York 2015 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. Printed on acid-free paper Humana Press is a brand of Springer Springer Science+Business Media LLC New York is part of Springer Science+Business Media (www.springer.com)
Preface
Over the last few decades, the study of pulmonary arterial hypertension (PAH) has become one of the most rapidly developing fields of cardiopulmonary medicine. This may seem surprising considering the relatively small number of patients who carry this diagnosis, but like many rare diseases that were once untreatable, interest in PAH has been spurred on by an intense desire to improve the outcome of those who are affected. At the same time, numerous discoveries in the field of pulmonary vascular biology have led to a marked shift in how we view the pulmonary circulation. Many of these discoveries have led directly to the development and licensing of over a dozen drugs in the last 20 years. When we began our training in pulmonary and cardiac medicine, primary pulmonary hypertension, as the disease was known then, had no approved treatment and less than 50 % of patients survived more than
Data Loading...
